Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia

This research is being done to evaluate effectiveness, safety, and tolerability of a study drug called momelotinib in participants with myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), MDS/MPN-not otherwise specified (MDS/MPN-NOS), MDS/MPN with neutrophilia (MDS/MPN-N), also called as atypical chronic myeloid leukemia, or chronic neutrophilic leukemia. Momelotinib will be added to standard treatment which usually includes a hypomethylating agent like azacitidine. Treatment options for this diagnosis remain limited and investigators need better treatments to help control the disease, im

Trial Details

NCT ID

NCT07071155

Phase

EARLY_PHASE1

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Status

RECRUITING

Cancer Type

Leukemia

Interventions

• Momelotinib
• Azacitidine

Locations (sample)

• Baltimore, Maryland, United States|39.29038,-76.61219

Key Eligibility Criteria

• Patients of age 18 or older
• Has a diagnosis of MDS/MPN or CNL by WHO or ICC diagnostic criteria:
• Chronic myelomonocytic leukemia
• MDS/MPN with neutrophilia, previously known as atypical chronic myeloid leukemia

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →